Table 2 Estimates of life-years after diagnosis, QALYs (Discounted) and Costs (Discounted)
From: Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma
Variable | Intervention | Control | Delta (Intervention-Control) |
|---|---|---|---|
No Radiation Benefit | |||
Life-years | 40.08 (33.19;45.76) | 39.01 (32.94;44.38) | 1.07 (0;2.39) |
QALY | 11 (9.16;12.59) | 10.62 (9.04;12.03) | 0.38 (0.08;0.77) |
Total Cost | $215,358 ($159,507; $232,728) | $216,742 ($161,250; $234,069) | $-1384 ($-3486; $1204) |
PLGG | $90,839 ($75,023; $108,612) | $90,244 ($74,885; $107,176) | $595 ($106; $2083) |
AE | $124,519 ($76,439; $151,351) | $126,498 ($78,418; $153,232) | $-1979 ($-4414; $1017) |
Radiation Benefit | |||
Life-years | 42.05 (34.98;47.29) | 41.44 (35.8;46.09) | 0.61 (−0.78;2.25) |
QALY | 11.46 (9.69;12.91) | 11.18 (9.68;12.49) | 0.28 (−0.11;0.72) |
Total Cost | $217,393 ($157,671; $236,003) | $218,624 ($155,869; $237,155) | $-1232 ($-3508; $1938) |
PLGG | $78,899 ($68,624; $91,119) | $75,259 ($66,745; $85,262) | $3640 ($984; $8397) |
AE | $138,494 ($81,832; $160,740) | $143,366 ($84,549; $164,863) | $-4872 ($-10,600; $-146) |